Zoetis Inc. Files 8-K Report
Ticker: ZTS · Form: 8-K · Filed: 2025-02-06T00:00:00.000Z
Sentiment: neutral
Topics: regulation-fd, financial-statements, filing
Related Tickers: ZTS
TL;DR
Zoetis filed a routine 8-K on Feb 6, 2025, no major news.
AI Summary
On February 6, 2025, Zoetis Inc. filed an 8-K report to disclose information under Regulation FD and to file financial statements and exhibits. The filing does not contain specific financial figures or material events beyond the standard reporting requirements for this form.
Why It Matters
This filing serves as a standard disclosure for Zoetis Inc., informing the public about regulatory compliance and the submission of financial documents.
Risk Assessment
Risk Level: low — The filing is a routine 8-K report and does not contain any new material information that would typically impact risk.
Key Players & Entities
- Zoetis Inc. (company) — Registrant
- February 6, 2025 (date) — Date of report
FAQ
What is the primary purpose of this 8-K filing by Zoetis Inc.?
The primary purpose of this 8-K filing is to report under Regulation FD and to file financial statements and exhibits.
What is the exact date of the earliest event reported in this filing?
The earliest event reported in this filing is dated February 6, 2025.
What is Zoetis Inc.'s principal executive office address?
Zoetis Inc.'s principal executive office is located at 10 Sylvan Way, Parsippany, New Jersey 07054.
What is Zoetis Inc.'s telephone number?
Zoetis Inc.'s telephone number is (973) 822-7000.
What is the SIC code for Zoetis Inc.?
The Standard Industrial Classification (SIC) code for Zoetis Inc. is 2834, which corresponds to Pharmaceutical Preparations.
From the Filing
0001555280-25-000022.txt : 20250206 0001555280-25-000022.hdr.sgml : 20250206 20250206162012 ACCESSION NUMBER: 0001555280-25-000022 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20250206 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250206 DATE AS OF CHANGE: 20250206 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Zoetis Inc. CENTRAL INDEX KEY: 0001555280 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 460696167 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35797 FILM NUMBER: 25597659 BUSINESS ADDRESS: STREET 1: 10 SYLVAN WAY CITY: PARSIPPANY STATE: NJ ZIP: 07054 BUSINESS PHONE: 973-822-7000 MAIL ADDRESS: STREET 1: 10 SYLVAN WAY CITY: PARSIPPANY STATE: NJ ZIP: 07054 8-K 1 zts-20250206.htm 8-K zts-20250206 0001555280 false 0001555280 2025-02-06 2025-02-06 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.  20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 6, 2025 Zoetis Inc. (Exact name of registrant as specified in its charter) Delaware 001-35797 46-0696167 (State or other jurisdiction (Commission File (I.R.S. Employer of incorporation) Number) Identification No.) 10 Sylvan Way Parsippany New Jersey 07054 (Address of principal executive offices) (Zip Code) ( 973 ) 822-7000 (Registrant's telephone number, including area code) Not Applicable (Former Name or Former Address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ☐     Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b)) ☐     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.01 per share ZTS New York Stock Exchange Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).                                      Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 7.01. Regulation FD Disclosure. On February 6, 2025, the Company declared a dividend of $0.500 per share for the second quarter of 2025. The dividend will be paid on June 3, 2025, to all holders of record of the Company’s common stock as of the close of business on April 21, 2025. The information set forth under this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of the Securities Exchange Act of 1934, as amended, or incorporated by reference in any filing under the Securities Act of 1933, as amended, regardless of any general incorporation language in such filing, unless expressl